Two months after U.S. President Donald Trump proclaimed DEI programs “illegal and immoral,” Roche has reportedly scrapped its high-profile five-year plan to increase the diversity of its leadership. Meanwhile, fellow Swiss company Novartis will no longer use diverse panels in its
read moreAfter a federal guilty plea in 2020, the former OxyContin drugmaker is required to reemerge from Chapter 11 bankruptcy as a public benefit company. More: Purdue Pharma files new .4B bankruptcy reorganization plan to settle opioid claims Source: fierce
read moreAfter charting similar moves throughout 2024, Pfizer this week completed a sale of its remaining shares in Haleon, taking home around 2.5 billion pounds sterling ($3.2 billion) for its stake in the standalone consumer health giant. GSK, which owned a
read moreEquipped with a 60-million-Canadian-dollar ($42 million) investment from the Canadian government, CDMO Delpharm is striking out on a multiyear campaign to modernize, upgrade and expand an injectables facility it bought from Sandoz in 2022. The plant, which supplies drugs locally
read moreFresh off a pivot from commercial pharma business to preclinical biotech, Aadi Bioscience has rebranded to better match its strategic reboot. More: Aadi Bioscience takes flight with new moniker: Whitehawk Therapeutics Source: fierce
read moreWith the fate of the BIOSECURE Act currently in limbo, WuXi AppTec is looking on the brighter side for 2025. Still, geopolitical uncertainties under the second Trump administration loom large over the Chinese contract research and manufacturing giant’s future. More:
read more© 1994 - 2026 B.M. Pharmaceuticals